StockData
Nautilus Biotechnology, Inc. logo

Nautilus Biotechnology, Inc. (NAUT) company profile

NAUTNasdaqLaboratory Analytical InstrumentsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 27, 2026Score 6/30
$2.36+0.26 (+12.38%)

Close on Nov 17, 2026Market cap $300.60MP/E –Yield –

About Nautilus Biotechnology

Laboratory Analytical Instruments, SIC 3826

Nautilus Biotechnology is a development-stage life sciences company that develops platform technology for single-molecule proteomic analysis. The company's core offering is the Nautilus Voyager platform, an end-to-end system that combines nanofabricated protein arrays, instruments, consumables, and machine-learning software to measure protein abundance and functional variants using its iterative mapping technique. Its applications encompass broadscale proteome profiling and targeted proteoform analysis, alongside fee-for-service proteomics analysis offerings. Nautilus serves researchers at biopharmaceutical companies, academic institutions, and research organizations.

The text does not state the company's corporate headquarters, but notes that it maintains an internal facility in San Carlos, California, alongside outsourced contract manufacturing operations. More than one-third of its workforce holds doctoral degrees. The company maintains research partnerships with academic and scientific organizations located in the United States and Qatar.

Summary of the business section of Nautilus Biotechnology's latest annual report, written by StockData.

Company profile

Company

Legal name
Nautilus Biotechnology, Inc.
Headquarters
Seattle, WA
Address
2701 Eastlake Ave East 98102
Phone
(206) 333-2001
Employees
130, Dec 31, 2025
Industry
Laboratory Analytical Instruments
Fiscal year ends
December 31
Auditor
PricewaterhouseCoopers LLP, San Jose, California

Stock & identifiers

Ticker
NAUT
Exchange
Nasdaq
IPO date
Aug 10, 2020
Shares outstanding
127M, Oct 22, 2026
Public float
$35.80M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
SEC CIK
1808805
CUSIP
63909J108
ISIN
US63909J1088
FIGI
BBG00W7G4M12
Share class FIGI
BBG00W7G4MV9
EIN
98-1541723

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Sujal M. PatelCEO, President, and Secretary, Director17,461,232
Parag MallickChief Scientist, Director20,493,392
Subramanian SankarSenior VP, Product Development91,250
Gwen E. WeldChief People Officer30,000
Kentaro SuzukiChief Marketing Officer4,000
Anna MowryCFO and Treasurer83,000
Matthew B. MurphyGeneral Counsel75,390
Nicholas A. NelsonCBO & Senior VP, Bus. Dev.–
Matthew S. McIlwainDirector6,479,845
Karen AkinsanyaDirector–
Farzad NazemDirector1,888,146
Epperly Melissa B,Director–
Matthew L. PosardDirector140,000

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryOption awardsIncentive payOtherTotalvs. prior year
Sujal Patel
President, Chief Executive Officer and Secretary
$535.00K$654.98K$227.38K$1.20K$1.42M-28%
Parag Mallick
Chief Scientist
$420.00K$282.15K$115.50K–$817.65K-21%
Anna Mowry
Chief Financial Officer
$440.00K$161.23K$110.00K$1.20K$712.43K-5%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

SPAC offering

Type
SPAC (blank check) IPO of units
Final prospectus filed
Aug 10, 2020
Offer price
$10.00
Exchange
Nasdaq
Lock-up ends (est.)
Feb 6, 2021

“This is an initial public offering of our Class A ordinary shares, par value $0.0001 per share, which we refer to as our public shares, at an initial public offering price per share of $10.00.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 130 employees, all based in the United States, over one-third of whom hold doctorate degrees.”

Corporate history

Events identified from SEC filings

DateEventDetails
May 2, 2025Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Jun 10, 2021Auditor changeChange in certifying accountant (8-K Item 4.01)
Jun 10, 2021Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Jun 8, 2021Name changeName changed from ARYA Sciences Acquisition Corp III to Nautilus Biotechnology, Inc.
Mar 26, 2021MergerRegistration of securities for a merger or exchange offer (S-4)
Aug 10, 2020IPOInitial public offering priced (424B4 prospectus)
Aug 6, 2020ListingRegistration of securities on an exchange (Form 8-A)

See a number that looks wrong?